The US government has ordered 300 million doses of a potential COVID-19 vaccine being developed by AstraZeneca and Oxford University and hopes first doses can be made available by October, the Department of Health and Human Services said Thursday.
"This contract with AstraZeneca is a major milestone in Operation Warp Speed’s work toward a safe, effective, widely available vaccine by 2021," HHS Secretary Alex Azar said in a statement.
The US has the world's worst coronavirus affliction, with over 1.52 million cases, including 91,664 deaths, according to data from its Centers for Disease Control and Prevention as of May 20.
-reuters-
LONDON - British pharmaceuticals group AstraZeneca has partnered with the University of Oxford to develop and distribute a coronavirus vaccine being trialed in the UK, the pair announced Thursday.
Human trials of the vaccine developed by the university's Jenner Institute began last week, with hundreds of people volunteering to be part of the study that has received £20 million ($24.7 million, 22.6 million euros) in government funding.
"The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford," said a joint statement.
"Under the agreement, AstraZeneca would be responsible for development and worldwide manufacturing and distribution of the vaccine."
Data from the first phase trial could be available next month, the statement said.
"Advancement to late-stage trials should take place by the middle of this year," it added.
The news comes after US scientists hailed the results of a major drug trial. People treated with Remdesivir recovered about 30 percent faster than those on a placebo.
Agence France-Presse
LONDON - Teenagers who use cannabis have a higher risk of developing depression and suicidal thoughts as young adults and should be made aware of those risks by parents and doctors, scientists said on Wednesday.
About 7 percent of cases of adolescent depression could be averted if cannabis use was eliminated, according to an analysis of data on mental illness among young people in the United States, Britain and Canada who used cannabis in their teens.
“Although the size of the negative effects of cannabis can vary ... and it is not possible to predict the exact risk for each teenager, the widespread use of cannabis among the young generations makes it an important public health issue,” said Andrea Cipriani, a professor of psychiatry at Britain’s Oxford University who co-led the work.
Cannabis is the most commonly used recreational drug by teenagers worldwide. In Canada, more than 20 percent of teens aged 15 to 19 years say they have used it in the past year. In England, for those aged 11 to 15, about 4 percent say they used cannabis in the last month.
The researchers said the results suggested that, if cannabis use were eliminated, there would be an estimated 400,000 fewer cases of depression in 18 to 34 year olds in the United States, 25,000 fewer in Canada and about 60,000 fewer in the Britain.
“It’s a big public health and mental health problem,” Cipriani told reporters at a briefing in London. “Adolescents should be made aware of the risk.”
The study, published in the journal JAMA Psychiatry and co-led by Cipriani and researchers at McGill University in Canada, was a systematic analysis pooling the best available evidence.
Teva slides on forecast, drags other generic drugmakers. It included 23,317 people from 11 international studies and looked at depression, anxiety and having suicidal thoughts in young adults.
Independent specialists asked to comment on the study said its findings were robust and important.
“Among young adults worldwide, depression is the leading cause of disability, and suicide is the most common cause of death,” said Joseph Firth, a specialist at Australia’s Western Sydney University.
By showing cannabis as a contributing factor to both, he said, the study showed the importance of seeking ways to reduce teenage cannabis use.
source: news.abs-cbn.com
